| Literature DB >> 32569789 |
Francisco Silvestre Brilhante Bezerra1, Andréa de Fátima Silva Rezende2, Mara Thaís de Oliveira Silva2, Ângela Sena-Lopes2, Mariana Roesch-Ely3, João Antônio Pêgas Henriques3, Francine Ferreira Padilha4, Vasco Ariston Carvalho Azevedo5, Ricardo Wagner Dias Portela6, Fabiana Kommling Seixas2, Tiago Veiras Collares2, Lucielli Savegnago2, Sibele Borsuk7.
Abstract
The immunomodulatory properties of Brazilian red propolis (BRP) have been already described. Also, propolis have been proved to have antibacterial activity on Corynebacterium pseudotuberculosis. An adjuvant effect of red propolis oil was able to induce a significant anti-C. pseudotuberculosis humoral immune response. Here, we demonstrate for the first time the immunostimulant property of BRP hydroalcoholic extract (BRPHE) in a recombinant vaccine against caseous lymphadenitis. Mice BALB/c were allocated in three groups inoculated with: sterile saline solution (G1); BRPHE (G2); or BRPHE combined with the C. pseudotuberculosis rCP01850 recombinant protein (G3) in two doses within a 21-days-interval. Blood samples were collected for the total IgG, IgG1 and IgG2a measurement. Mice were challenged with a virulent C. pseudotuberculosis strain, and other 6 mice were used for IFN-γ and IL-10 levels determination after splenocyte stimulation with the recombinant antigen. G3 showed higher significant levels of antibodies on the 42nd experimental day, with a high IgG2a/IgG1 proportion. G2 and G3 presented significant production of IFN-γ and IL-10, while G3 presented the higher levels of IFN-γ (p < 0.05). After challenge, G2 showed a survival rate of 20%, while 70% of mice from G3 survived the experimental challenge. In conclusion, BRPHE used alone has immunostimulant properties specially on cellular immune response, and when used in combination with the recombinant protein rCP01850 induces cellular and humoral immune responses as well as a significant survival of inoculated mice.Entities:
Keywords: Adjuvant; Caseous lymphadenitis; Natural products; Vaccine trials
Mesh:
Substances:
Year: 2020 PMID: 32569789 DOI: 10.1016/j.micpath.2020.104354
Source DB: PubMed Journal: Microb Pathog ISSN: 0882-4010 Impact factor: 3.738